Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 245Carcinoma, Non-Small-Cell Lung 225Prostatic Neoplasms 113Neoplasms 104Multiple Myeloma 90Neoplasm Metastasis 75Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 66Ovarian Neoplasms 61Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 47Melanoma 46Leukemia, Lymphocytic, Chronic, B-Cell 44Carcinoma, Renal Cell 43Urinary Bladder Neoplasms 41Stomach Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Triple Negative Breast Neoplasms 40Recurrence 40Brain Neoplasms 40Myasthenia Gravis 37Small Cell Lung Carcinoma 35Lymphoma, Follicular 35Nasopharyngeal Carcinoma 34Head and Neck Neoplasms 33Pancreatic Neoplasms 32Rectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 30Colonic Neoplasms 29

Interventions

eribulin 1Vinorelbine 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HR+HER2- Breast Cancer × 1 year × Clear all
NCT06343948 2026-04-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
383 enrolled
Breast

HR+HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡